Needham & Company LLC restated their hold rating on shares of Sight Sciences (NASDAQ:SGHT – Free Report) in a report published on Friday, Benzinga reports.
Sight Sciences Trading Up 6.2 %
NASDAQ:SGHT traded up $0.35 during trading hours on Friday, hitting $5.96. 92,267 shares of the company were exchanged, compared to its average volume of 171,268. The stock has a market capitalization of $295.32 million, a price-to-earnings ratio of -5.32 and a beta of 2.73. Sight Sciences has a one year low of $1.04 and a one year high of $11.00. The company has a fifty day simple moving average of $5.11 and a 200 day simple moving average of $4.19. The company has a current ratio of 13.29, a quick ratio of 12.65 and a debt-to-equity ratio of 0.26.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. The business had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $18.70 million. Sight Sciences had a negative return on equity of 42.84% and a negative net margin of 67.18%. During the same period in the prior year, the business posted ($0.35) earnings per share. Sell-side analysts expect that Sight Sciences will post -1.04 EPS for the current fiscal year.
Insider Buying and Selling
Hedge Funds Weigh In On Sight Sciences
Several institutional investors have recently made changes to their positions in the stock. UBS Group AG grew its stake in shares of Sight Sciences by 20,282.6% in the 4th quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after buying an additional 2,881,750 shares during the period. First Eagle Investment Management LLC grew its stake in Sight Sciences by 45.6% in the third quarter. First Eagle Investment Management LLC now owns 587,297 shares of the company’s stock valued at $1,979,000 after acquiring an additional 183,912 shares during the period. Jackson Square Partners LLC grew its stake in Sight Sciences by 12.0% in the fourth quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock valued at $8,409,000 after acquiring an additional 174,737 shares during the period. RTW Investments LP acquired a new position in shares of Sight Sciences during the fourth quarter worth approximately $850,000. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Sight Sciences by 198.1% in the 4th quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company’s stock worth $305,000 after purchasing an additional 39,333 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.
Sight Sciences Company Profile
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
See Also
- Five stocks we like better than Sight Sciences
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 4/29 – 5/3
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Following Congress Stock Trades
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.